Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38227 | 0.93 | HPGDS (1.00) | HPGDSEPHX2L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL3200853 | 0.82 | HPGDS (0.67) | HPGDSL3MBTL1KDM4E | |
| SCHEMBL13876385 | 0.76 | HPGDS (0.64) | HPGDSEPHX2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL38498 | 0.76 | HPGDS (0.63) | HPGDSLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5128689 | 0.74 | HPGDS (0.59) | HPGDSNR1H4EPHX2LMNASMN1; SMN2 | |
| SCHEMBL16495657 | 0.74 | HPGDS (1.00) | HPGDSNR1H4EPHX2L3MBTL1HDAC1 | |
| SCHEMBL27822779 | 0.74 | L3MBTL1 (0.81) | HPGDSNR1H4EPHX2L3MBTL1SMN1; SMN2 | |
| SCHEMBL14457462 | 0.74 | HPGDS (0.60) | HPGDSEPHX2LMNASMN1; SMN2RAB9A | |
| SCHEMBL44435 | 0.73 | HPGDS (0.64) | HPGDS | |
| SCHEMBL14082857 | 0.73 | HPGDS (0.67) | HPGDSNR1H4EPHX2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576536-B1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | UNIV QUEENSLAND (AU) | 2016-09-14 | — | — | EP | disclosed |
| US-9199976-B2 | Haematopoietic-prostaglandin D2 synthase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-12-01 | — | — | US | disclosed |
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137684-A1 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | HPGDS, PTGES, PTGIS | HPGDS 1/4885NR1H4 1360/4885EPHX2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.